

# EVALUATION OF TREATMENT ADHERENCE WITH RILPIVIRINE/ EMTRICITABINE/TENOFOVIR

TRUJILLANO A, FRANCO JJ, GARCÍA M,  
BERNAL E, CABALLERO C, VALENCIA C

HGU REINA SOFÍA  
MURCIA, SPAIN



ABSTRACT NUMBER  
DI - 053

1

## BACKGROUND

Rilpivirine is a recently authorized antiretroviral. Adherence is essential in this kind of drug

## PURPOSE

To evaluate treatment adherence with rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) using the SMAQ questionnaire and pharmacy dispensing records (FDR) and the correlation between these in HIV/AIDS mono-infected patients

2

## MATERIAL

### AND METHOD

Prospective observational study. We included patients treated with RPV/FTC/TDF from September 2013 until September 2014 with adherence data available of at least 3 months. Demographics data and reason for treatment were collected.

Adherence was calculated across the SMAQ questionnaire (qualitative and semi-quantitative) and FDR, considering the patient adherent when any of these parameters was  $\geq 95\%$ . The correlation between the methods was assessed using the kappa ( $\kappa$ ) index

3

## RESULTS


### 33 patients started treatment with RPV/FTC/TDF

21 were included in the study

71% were men (Average age:  $40 \pm 10$  years)

38% were treatment-naïve and the rest were changes of therapeutic strategy (33% adverse reactions and 29% simplification of treatment strategies)

### ADHERENCE



The results between the three analysis only coincided in 6 patients

As for the results of  $\kappa$  index, we observed the following strength of agreement: fair between the SMAQ quantitative and qualitative questionnaires ( $\kappa=0.22$ ) and slight between the SMAQ qualitative questionnaire and FDR ( $\kappa=0.04$ ) and between semi-quantitative SMAQ and FDR questionnaire ( $\kappa=0.01$ )

4

## CONCLUSIONS

- Our study highlights a low adherence to treatment obtained with the SMAQ questionnaire (both qualitative and semi-quantitative). It may be due to both the inflexibility of the questions and because of the patient assessment. These results could be improved through a pharmacist intervention in the monthly clinical review
- Correlation between the three methods was low, so their use in isolation may give erroneous results in predicting adherence. However, with this way, "hidden" non-adherent patients (adherent FDR and non-adherent SMAQ) and "masked" non-adherent patients (non-adherent FDR and adherent SMAQ) could be detected